US Edition
Published • loading... • Updated
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Lupin to present Phase 1a clinical trial data of STING agonist LNP3693 at ESMO Congress 2025 - Express Pharma
Global pharma company Lupin announced that it will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, from October 17 to October 21, 2025. The presentation, titled “A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,” will be featured in the Investigational Immuno…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium